Published in Blood on September 27, 2012
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer (2014) 3.37
Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther (2013) 1.27
Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita. J Clin Invest (2015) 1.16
DNA damage responses and oxidative stress in dyskeratosis congenita. PLoS One (2013) 1.01
Role of p53 in regulating tissue response to radiation by mechanisms independent of apoptosis. Transl Cancer Res (2013) 0.96
USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis (2013) 0.96
RCAD/Ufl1, a Ufm1 E3 ligase, is essential for hematopoietic stem cell function and murine hematopoiesis. Cell Death Differ (2015) 0.92
Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia. Leukemia (2013) 0.91
Repression of p53-target gene Bbc3/PUMA by MYSM1 is essential for the survival of hematopoietic multipotent progenitors and contributes to stem cell maintenance. Cell Death Differ (2016) 0.88
Biosensors in clinical practice: focus on oncohematology. Sensors (Basel) (2013) 0.81
MicroRNA 155 control of p53 activity is context dependent and mediated by Aicda and Socs1. Mol Cell Biol (2015) 0.80
DNA damage response, redox status and hematopoiesis. Blood Cells Mol Dis (2013) 0.80
Acute DNA damage activates the tumour suppressor p53 to promote radiation-induced lymphoma. Nat Commun (2015) 0.80
p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia. Blood (2016) 0.79
Altered Expression of Genes in Signaling Pathways Regulating Proliferation of Hematopoietic Stem and Progenitor Cells in Mice with Subchronic Benzene Exposure. Int J Environ Res Public Health (2015) 0.77
Alpha-enolase is upregulated on the cell surface and responds to plasminogen activation in mice expressing a ∆133p53α mimic. PLoS One (2015) 0.77
Direct regulation of p53 by miR-142a-3p mediates the survival of hematopoietic stem and progenitor cells in zebrafish. Cell Discov (2015) 0.76
Disease-specific mutations in mature lymphoid neoplasms: recent advances. Cancer Sci (2014) 0.76
Mdm2 Phosphorylation Regulates Its Stability and Has Contrasting Effects on Oncogene and Radiation-Induced Tumorigenesis. Cell Rep (2016) 0.75
Impairment of fetal hematopoietic stem cell function in the absence of Fancd2. Exp Hematol (2016) 0.75
The Pu.1 target gene Zbtb11 regulates neutrophil development through its integrase-like HHCC zinc finger. Nat Commun (2017) 0.75
Gamma-Tocotrienol Modulates Radiation-Induced MicroRNA Expression in Mouse Spleen. Radiat Res (2016) 0.75
Expansion of the hematopoietic stem cell compartment is necessary but not sufficient for gain-of-function mutant p53 R248Q to accelerate lymphomagenesis. Cell Death Differ (2015) 0.75
Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. Oncogene (2017) 0.75
Haploinsufficient tumor suppressor genes. Adv Med Biol (2017) 0.75
The Inhibitory Effect of Ginger Extract on Ovarian Cancer Cell Line; Application of Systems Biology. Adv Pharm Bull (2017) 0.75
Surfing the p53 network. Nature (2000) 35.36
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 25.54
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell (2005) 24.00
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
Regulation of p53 stability by Mdm2. Nature (1997) 18.20
Blinded by the Light: The Growing Complexity of p53. Cell (2009) 17.75
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 16.60
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06
p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (1993) 13.46
Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science (1996) 12.54
Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (1998) 11.90
A model for p53-induced apoptosis. Nature (1997) 11.38
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett (1997) 11.19
Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science (1998) 10.89
Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science (2000) 10.81
Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (1993) 10.72
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (1995) 10.18
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
p53 mutant mice that display early ageing-associated phenotypes. Nature (2002) 10.05
p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science (2003) 9.94
Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature (2009) 9.75
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer (2006) 8.83
Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature (2009) 8.70
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature (1995) 8.68
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science (2000) 7.85
Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell (2003) 7.60
The antioxidant function of the p53 tumor suppressor. Nat Med (2005) 7.57
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature (1991) 7.49
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
The p53 pathway. J Pathol (1999) 6.79
The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell (2009) 6.64
The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet (1999) 6.23
The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol (1995) 4.77
Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells. Nature (2004) 4.68
Inactivation of the p53 pathway in retinoblastoma. Nature (2006) 4.57
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature (2006) 4.57
Ribosomopathies: human disorders of ribosome dysfunction. Blood (2010) 4.43
p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell (2009) 4.30
Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet (2001) 4.23
"Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J (2002) 4.17
MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J (1996) 4.13
The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer (2003) 3.89
IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res (1998) 3.74
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet (2003) 3.61
p53 suppresses the self-renewal of adult neural stem cells. Development (2006) 3.35
Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet (2006) 3.17
Differential expression of novel potential regulators in hematopoietic stem cells. PLoS Genet (2005) 3.11
Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol (2002) 3.10
Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood (2008) 3.05
Stem cells: The promises and perils of p53. Nature (2009) 3.01
A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med (2009) 2.89
Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood (2010) 2.84
Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors. Nature (2008) 2.82
Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia. Hum Mutat (2007) 2.73
p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell (2010) 2.65
p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet (1994) 2.61
Transcription factor Gfi1 regulates self-renewal and engraftment of hematopoietic stem cells. EMBO J (2004) 2.57
Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature (1974) 2.56
P53 and radiation responses. Oncogene (2003) 2.52
Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell (2008) 2.46
Progression of interleukin-2 (IL-2)-dependent rat T cell lymphoma lines to IL-2-independent growth following activation of a gene (Gfi-1) encoding a novel zinc finger protein. Mol Cell Biol (1993) 2.37
Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A (2007) 2.36
Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev (2006) 2.35
mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol (2003) 2.32
Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell (2006) 2.32
Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell (2009) 2.28
Mouse hematopoietic stem-cell antigen Sca-1 is a member of the Ly-6 antigen family. Proc Natl Acad Sci U S A (1989) 2.24
Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits. Blood (2006) 2.22
Establishment of a normal hematopoietic and leukemia stem cell hierarchy. Cold Spring Harb Symp Quant Biol (2008) 2.13
Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J (2006) 2.12
p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science (2009) 2.11
The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood (2006) 2.10
Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A (1998) 2.00
Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol Cell (2009) 2.00
Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J (1997) 1.96
Low doses of radiation increase the latency of spontaneous lymphomas and spinal osteosarcomas in cancer-prone, radiation-sensitive Trp53 heterozygous mice. Radiat Res (2003) 1.92
Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood (1993) 1.90
A transgenic mouse model demonstrates a dominant negative effect of a point mutation in the RPS19 gene associated with Diamond-Blackfan anemia. Blood (2010) 1.88
p53 at a glance. J Cell Sci (2010) 1.88
Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol Cell Biol (2004) 1.85
Targeted disruption of the ribosomal protein S19 gene is lethal prior to implantation. Mol Cell Biol (2004) 1.85
Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J (2003) 1.85
A Limited role for p21Cip1/Waf1 in maintaining normal hematopoietic stem cell functioning. Stem Cells (2006) 1.84
The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol (2007) 1.83
Irradiation selects for p53-deficient hematopoietic progenitors. PLoS Biol (2010) 1.65
Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol (2007) 1.64
Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J (2004) 1.63
Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp Hematol (2003) 1.59
Mutation of ribosomal protein RPS24 in Diamond-Blackfan anemia results in a ribosome biogenesis disorder. Hum Mol Genet (2008) 1.52
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A (2011) 1.51
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell (2010) 1.49
p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ (2010) 1.47
Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica (2010) 1.47
Diamond Blackfan anemia: a disorder of red blood cell development. Curr Top Dev Biol (2008) 1.45
Do reactive oxygen species play a role in myeloid leukemias? Blood (2011) 1.43
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res (2007) 4.42
Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med (2011) 3.74
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet (2003) 3.61
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
MDM2, an introduction. Mol Cancer Res (2003) 2.87
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 2.77
Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem (2002) 2.68
Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet (2003) 2.52
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell (2012) 2.04
20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer (2009) 2.00
Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep (2007) 1.96
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol (2003) 1.93
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood (2009) 1.82
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A (2006) 1.82
Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol (2005) 1.79
Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol (2006) 1.76
Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A (2002) 1.72
Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet (2003) 1.68
Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell (2011) 1.67
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood (2013) 1.64
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer (2010) 1.64
An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest (2007) 1.64
Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol (2007) 1.64
Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Mol Cell Biol (2007) 1.58
p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One (2008) 1.55
Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest (2011) 1.54
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A (2011) 1.51
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell (2010) 1.49
Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res (2006) 1.47
Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol (2004) 1.44
p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci U S A (2006) 1.41
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res (2009) 1.41
Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One (2009) 1.39
RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. Carcinogenesis (2003) 1.37
Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. Leuk Res (2009) 1.37
Distinct roles of Mdm2 and Mdm4 in red cell production. Blood (2006) 1.36
Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol (2006) 1.35
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res (2012) 1.33
Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res (2003) 1.32
The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity (2010) 1.31
Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res (2008) 1.27
Multiple stress signals activate mutant p53 in vivo. Cancer Res (2011) 1.27
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol (2011) 1.24
Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res (2010) 1.23
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res (2008) 1.21
Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest (2011) 1.21
p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res (2010) 1.21
Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation (2007) 1.21
Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell (2010) 1.21
EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res (2008) 1.17
High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol (2007) 1.17
Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc Natl Acad Sci U S A (2014) 1.16
Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathol (2010) 1.15
Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis (2009) 1.15
Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis (2002) 1.14
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci (2008) 1.14
p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res (2010) 1.12
The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev (2013) 1.11
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? Hematol Oncol (2006) 1.11
Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep (2010) 1.11
Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res (2007) 1.10
Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res (2011) 1.10
Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene (2002) 1.09
p21 stability: linking chaperones to a cell cycle checkpoint. Cancer Cell (2005) 1.06
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol (2013) 1.06
Li-Fraumeni syndrome: a p53 family affair. Cell Cycle (2005) 1.05
E2F3 is a mediator of DNA damage-induced apoptosis. Mol Cell Biol (2009) 1.04
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res (2013) 1.04
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood (2006) 1.04
Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci (2014) 1.02
Evolution of therapies for chronic myelogenous leukemia. Cancer J (2011) 1.01
HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol (2006) 1.00
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res (2008) 1.00
Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma. Sarcoma (2010) 0.99
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat (2014) 0.97
p53 and MDM2: antagonists or partners in crime? Cancer Cell (2009) 0.96
Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. Mutat Res (2003) 0.96
The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer (2011) 0.96
Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome (2007) 0.94
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res (2006) 0.94
ASPP2 suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63. Proc Natl Acad Sci U S A (2013) 0.94
Significance of cytogenetic abnormalities in patients with polycythemia vera. Leuk Lymphoma (2013) 0.93
Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. Differentiation (2009) 0.92
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res (2006) 0.91
Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One (2010) 0.91
The Many Faces of MDM2 Binding Partners. Genes Cancer (2012) 0.90
Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene (2004) 0.89
Tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med (2007) 0.89